Geron (GERN)
(Delayed Data from NSDQ)
$3.30 USD
-0.01 (-0.30%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $3.29 -0.01 (-0.30%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
GERN 3.30 -0.01(-0.30%)
Will GERN be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for GERN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GERN
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Company News for Mar 18, 2024
GERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
Implied Volatility Surging for Geron (GERN) Stock Options
Geron (GERN) Upgraded to Buy: Here's Why
Other News for GERN
GERN May 3rd Options Begin Trading
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Geron announces pricing of $150M underwritten offering
Geron prices $150M offering of common stock and warrants at $3.00 per share
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)